April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Insulin-Induced Betacellulin Cleavage Regulates the Blood-Retinal Barrier
Author Affiliations & Notes
  • M. Sugimoto
    Department of Ophthalmology, Cole Eye Institute, Cleveland Clinic, Lerner College of Medicine @ CWRU, Cleveland, Ohio
  • A. Cutler
    Department of Ophthalmology, Cole Eye Institute, Cleveland Clinic, Lerner College of Medicine @ CWRU, Cleveland, Ohio
  • B. Anand-Apte
    Department of Ophthalmology, Cole Eye Institute, Cleveland Clinic, Lerner College of Medicine @ CWRU, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  M. Sugimoto, None; A. Cutler, None; B. Anand-Apte, None.
  • Footnotes
    Support  US National Institute of Health EY016490, CA106415, EY015638, unrestricted Grant from Research to Prevent Blindness and RPB Lew Wasserman award to BA-A
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5626. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Sugimoto, A. Cutler, B. Anand-Apte; Insulin-Induced Betacellulin Cleavage Regulates the Blood-Retinal Barrier. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5626.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : While large-scale clinical trials have identified hyperglycemia as a risk factor for progression of diabetic retinopathy (DR), some studies have suggested a worsening of DR following insulin therapy. The exact molecular mechanisms underlying the initial exacerbation of microvascular complications in the first two years of intensive insulin therapy remains unknown. We have previously reported that betacellulin (BTC), a member of the epidermal growth factor family plays a critical role in the induction of increased vascular permeability in the diabetic retina. In the present study we tested the hypothesis that the effect of insulin on the blood-retinal barrier (BRB) is mediated via BTC.

Methods: : The localization of BTC protein expression was evaluated by immunohistochemistry and western blot analysis using a retinal pigment epithelial cell line (ARPE-19), Müller cell line, retinal endothelial cell line and post-mortem human retina sections. The effect of increasing concentrations of insulin on the tight junction protein, zonula occludens-1 (ZO-1), BTC cleavage and activation as well as a disintegrin and metalloproteinase-10 (ADAM-10) in ARPE-19 was evaluated. The signaling pathways utilized by insulin in exacerbating retinal vascular permeability were also evaluated in vivo using streptozotocin-induced diabetic mice with and without insulin therapy.

Results: : Western blot analyses identified the presence of BTC protein in cultured human retinal endothelial cells, Müller cells and ARPE-19. Immunohistochemistry studies on human retina determined BTC to be predominantly localized to the RPE. Using ARPE-19, BTC was found to be co-localized with ZO-1 in tight junctions. Exposure of ARPE-19 to insulin resulted in the disruption of ZO-1 and cleavage/activation of BTC mediated by ADAM-10. Similar pathways were activated in the retinas of diabetic mice treated with insulin.

Conclusions: : Insulin induces the activation of BTC through ADAM-10 and causes a disruption of the outer BRB. The transient worsening of DR in some diabetic patients following intensive insulin therapy may be a result of these mechanisms.

Keywords: diabetes • diabetic retinopathy • retinal pigment epithelium 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×